NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization171.9 mln
Float40.73 mln
Earnings Date05/19/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
7.40
Transformational upside
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.44
Low leverage
ROE
-98.16
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Acumen Pharmaceuticals is a clinical-stage company working to develop new treatments for Alzheimer's disease. Its lead drug, Sabirnetug, is designed to target a specific form of amyloid-beta protein believed to drive the disease, and is currently being evaluated in a Phase 2 clinical trial following encouraging Phase 1 results. The company is also working with Halozyme to develop a version of the drug that patients could take by injection under the skin rather than through an IV. Founded in 1996 and based in Newton, Massachusetts, Acumen remains focused on bringing meaningful options to patients affected by Alzheimer's.
